Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity by Harper, James et al.
Recombinant Newcastle disease virus immunotherapy 
drives oncolytic effects and durable systemic antitumor 
immunity
HARPER, James, BURKE, Shannon, TRAVERS, Jon, RATH, Nicola, 
LEINSTER, Andrew, NAVARRO, Christel, FRANKS, Ruth, LEYLAND, 
Rebecca <http://orcid.org/0000-0002-0310-381X>, MULGREW, Kathy, 
MCGLINCHEY, Kelly, BROWN, Lee, DOVEDI, Simon J., KOOPMANN, Jens-
Oliver, DURHAM, Nicholas M., CHENG, Xing, JIN, Hong, EYLES, Jim, 
WILKINSON, Robert W. and CARROLL, Danielle
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/28790/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
HARPER, James, BURKE, Shannon, TRAVERS, Jon, RATH, Nicola, LEINSTER, 
Andrew, NAVARRO, Christel, FRANKS, Ruth, LEYLAND, Rebecca, MULGREW, 
Kathy, MCGLINCHEY, Kelly, BROWN, Lee, DOVEDI, Simon J., KOOPMANN, Jens-
Oliver, DURHAM, Nicholas M., CHENG, Xing, JIN, Hong, EYLES, Jim, WILKINSON, 
Robert W. and CARROLL, Danielle (2021). Recombinant Newcastle disease virus 
immunotherapy drives oncolytic effects and durable systemic antitumor immunity. 
Molecular Cancer Therapeutics. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
   
 
1 
Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and 







































, Robert W Wilkinson
1





Oncology R&D, AstraZeneca, Milstein Building, Granta Park, Cambridge, CB21 6GH, UK  
2
Oncology R&D, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA  
3
BioPharmaceutical R&D, AstraZeneca, South San Francisco, CA, USA 
 
 
*Correspondence and requests for materials should be addressed to J.H. (email: 
james.harper@astrazeneca.com). 
Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK, +44 (0) 203 749 6269 
 
The authors declare no potential conflicts of interest 
 
  
on June 28, 2021. © 2021 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 17, 2021; DOI: 10.1158/1535-7163.MCT-20-0902 




A recombinant Newcastle Disease Virus (NDV), encoding either a human (NDVhuGM-CSF, 
MEDI5395) or murine (NDVmuGM-CSF) GM-CSF transgene, combined broad oncolytic 
activity with ability to significantly modulate genes related to immune functionality in human 
tumor cells.  Replication in murine tumor lines was significantly diminished relative to 
human tumor cells. Nonetheless, intratumoral injection of NDVmuGM-CSF conferred 
antitumor effects in three syngeneic models in vivo; with efficacy further augmented by 
concomitant treatment with anti-PD-1/L-1 or T cell agonists. Ex vivo immune-profiling, 
including TCRseq, revealed profound immune-contexture changes; consistent with priming 
and potentiation of adaptive immunity and tumor-microenvironment (TME) re-programming 
towards an immune-permissive state. CRISPR modifications rendered CT26 significantly 
more permissive to NDV replication, and in this setting NDVmuGM-CSF confers immune-
mediated effects in the non-injected tumor in vivo. Taken together the data supports the thesis 
that MEDI5395 primes and augments cell mediated antitumor immunity and has significant 
utility as a combination partner with other immunomodulatory cancer treatments.  
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Treatment of cancer has been revolutionized by the development of immune checkpoint 
blockade (ICB) therapies; which confer durable clinical benefit in a subset of patients
1,2
. 
Defining predictive biomarkers of response to ICB therapies has become a priority, with 
significant progress made with respect to genetic signatures (e.g. microsatellite instability) 
and inhibitory receptor ligand expression patterns (e.g. PD-L1) linked to treatment 
outcomes
3,4
. Clinical response to ICB is more frequently observed in “inflamed” tumors; i.e. 
those often associated with high mutational burden and/or high PD-L1 expression and higher 
densities of cytotoxic CD8+ T lymphocytes (CTLs) and NK cells. Conversely, “cold” tumors 
have a paucity of these effector populations and tend to be unresponsive to ICB
5
. In some 
cancers T cells may be present, but either “excluded” from the tumor nests or actively 
suppressed by the local tumor microenvironment (TME)
6
. Identifying treatments which 
transform TMEs from an ICB resistant to sensitive phenotype is a priority to enable rational 
immunotherapy combinations with enhanced clinical efficacy.   
Oncolytic Viruses (OVs) could potentiate immunological responses in patients where ICB 
therapy is currently not effective
7
. OVs selectively infect and replicate in tumor cells, leading 
to oncolysis, an inherently immunogenic process, with release of tumor associated antigens, 
damage associated molecular patterns (DAMPS) and proinflammatory cytokines culminating 
in the activation of antigen presenting cells, recruitment of immune effector cells (e.g. T and 
NK cells) and de novo priming of T cell mediated anti-tumor immunity
8
. The intrinsic 
oncolytic activity and immunomodulatory properties of some viruses can be further 
augmented by introduction of immunomodulatory transgenes; with expression limited to the 
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NDV has a number of distinguishing characteristics that make it an attractive OV platform: 
(i) low seroprevalence, (ii) precedence of safe use in humans
10
, (iii) ability to infect a wide 
variety of tumor types through binding to sialic acids on the tumor cell surface, (iv) potential 
for intravenous administration and (v) option to include therapeutic transgenes with tumor 




MEDI5395, is a genetically modified NDV that retains oncolytic activity whilst also 
engineered to express human granulocyte/macrophage colony-stimulating factor (GM-CSF) 
from infected tumor cells
12
. Infection of human PBMC’s with MEDI5395 leads to 
polarisation of monocyte populations and an enhancement in cell surface molecules and 
cytokine profiles associated with an antitumor phenotype. NDV-mediated expression of GM-
CSF results in enhancement of monocyte activation compared to NDV lacking the transgene 
13
.   
In this study we demonstrate that MEDI5395 has broad oncolytic and proinflammatory 
activity across a range of preclinical human tumor models. We extend these observations to 
immune competent murine syngeneic models using a surrogate NDV (NDVmuGM-CSF) 
where we show that treatment leads to re-polarization of the TME and to robust antitumor 
activity. Efficacy was further potentiated when NDVmuGM-CSF was combined with ICB 
antibodies or T cell agonists. NDVmuGM-CSF treatment induced immune-mediated 
anenestic (abscopal) effects in CT26 tumors modified to facilitate enhanced viral replication 
through CRISPR-mediated disruption of Rig-I and Ifnar1; consistent with induction of a 
systemic adaptive immune response. These results support the development of MEDI5395 as 
a broad immuno-oncology based therapeutic and combination partner with T-cell targeted 
immunotherapies. The data also provide important insight into potential patient stratification 
strategies, and early biomarkers of response that could be employed in the clinic. 
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MATERIALS & METHODS 
 
In vitro tumor cell infectivity assay  
A total of 10,000 cells per well were plated in a 96-well plate in cell-specific full-growth 
medium and allowed to adhere for 4 h. Cells were subsequently treated with a dose range of 
virus (MOI 10–0.00001). Staurosporine 5 µM (Sigma) was used as a positive death-inducing 
control. At 72 h after infection, the supernatant from cells infected at MOI 0.1 was used to 
assess GM-CSF expression levels by electrochemiluminescent immunoassay (Meso Scale 
Diagnostics), according to the manufacturer’s instructions, and virus titre via plaque assay.
12
 
Cell viability at each MOI was measured with Cell Titer Glo (Promega). All experiments 
were performed in triplicate and were repeated at least four times. Details of all cell lines 
used can be found in Supplemental Table S1. 
 
Transcriptomic analysis and cytokine measurement of virus-infected cells 
NDV-GFP was used to determine the MOI that resulted in 100% infectivity of 6 × 10
5
 cells 
in six-well plates at 24 h after infection for each cell line. For human cell lines, the following 
MOIs were used: HT1080, MOI 0.1; DU145, MOI 0.5; NCIH358, MOI 0.5; OVCAR4, MOI 
0.5; CAL27, MOI 2.0; CT26, MOI 10; 4T1, MOI 5.0; and B16F10, MOI 0.5. Cells were 
incubated with virus for 24 h, after which supernatant was removed and chemokine and 
cytokine levels were analysed with Luminex-based assays (eBioscience). 
 
Cells were either harvested for FACS analysis or used to prepare RNA according to the 
manufacturer’s instructions (Qiagen). For microarrays, 100 ng of RNA was used and 
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biological replicates were run for each condition. Whole-transcriptome amplification, reverse 
transcription and DNA labelling, fragmentation, and array hybridisation were performed 
according to the manufacturer’s instructions for Affymetrix HTA 2.0 arrays. Arrays were 
hybridised, washed, and scanned in randomised batches of eight to minimise batch effects. 
Files were processed with Affymetrix Expression Console, and differential expression was 
determined with Affymetrix Transcriptome Analysis Console.  
 
Animal husbandry and in vivo experiments 
 
In vivo experiments used 8–10-week-old female C57BL/6J or BALB/c mice (Charles River 
Laboratories) for syngeneic models. All experiments in the UK were conducted under a U.K. 
Home Office Project Licence in accordance with the U.K. Animals (Scientific Procedures) 
Act 1986 and in accordance with EU Directive EU 2010/63/EU. All experiments in the USA 
were conducted in an Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC) – accredited and United States Department of Agriculture (USDA)-licensed 
facility. All mice were housed in sterile and standardised environmental conditions. Mice 
received autoclaved food and bedding and drinking water ad libitum. Mice were shaved on 
the right flank and anaesthetised with isoflurane, and all tumor cells were implanted 
subcutaneously into the right flank. For the rechallenge or dual-flank model, the left flank 
was also utilised as an implantation site. 
Group sizes for all studies were powered on the basis of existing tumor growth data to test for 
>50% tumor growth inhibition. Power calculation was conducted with a one-sided, two-
sample t test at 5% significance. Animals were randomised to treatment groups on the basis 
of tumor volume before the first treatment. Tumors were routinely measured with calipers, 
and data were automatically captured with the dasHost system (Microsoft). A partial response 
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7 
to therapy was deemed to occur when median survival of that animal was greater than two 
standard deviations from the median survival of the control group. A complete response to 
therapy was deemed to occur when tumors had 5 sequential measurements below 200mm
3
 
following cessation of treatment.  
NDVmuGM-CSF was administered IT at 20 µL. Antibodies to PD-1 (clone RMP4-14; Bio X 
Cell), PD-L1 (mouse immunoglobulin 1 [IgG1]; AstraZeneca), GITRL-FP (mouse IgG2a; 
AstraZeneca), and OX40L-FP (mouse IgG1; AstraZeneca) were all administered 
intraperitoneally (IP). For live imaging with NDV-luciferase, animals were injected with 100 
µL of 33-mg/mL D-Luciferin (Perkin Elmer). Under recoverable isoflourane anaesthesia, 
animals were imaged with the IVIS bioluminescence system (Perkin Elmer) 10 min after IP 
injection. 
 
ELISPOT detection of antigen reactive T cells 
Spleens were harvested from control or previously “cured” NDVmuGM-CSF treated animals 
following CT26 tumor re-challenge. Spleens were dissociated to a single-cell suspension 
through a 70 µm nylon mesh and depleted of red blood cells with lysing buffer (Sigma) 
before being resuspended in media. 3 x 10
5
 cells were plated into 96-well ELISPOT PVDF 
plates (Millipore) which had been coated with anti-IFN-γ capture antibody, as per 
manufacturer’s instructions (MABTECH). Cells were pulsed with 10 uM control (beta-
galactosidase peptide) or AH-1 peptide (both from MBL International). The assays were 
incubated at 37° C for 36 hr and spots were detected as per manufacturer’s directions. Spots 
were enumerated with an ImmunoSpot plate reader (CTL Europe). 
 
TCR sequencing from CT26 tumors 
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CT26 tumors were excised and DNA was prepared according to the manufacturer’s 
instructions (Qiagen) and shipped to Adaptive Biotechnologies for TCR-β sequencing and 
analysis with the ImmunoSeq platform. 
 
Clustergram and abacus plot 
Genes that were differentially expressed after NDV-GFP infection were identified by volcano 
plot analysis (two-fold change, P < 0.05) and used for pathway analysis. Data for each cell 
line were submitted separately to the Reactome pathway engine, and all pathway results were 
merged in a single output file that was subsequently ranked by the false discovery rate for 
each pathway. Abacus plots represent the median expression levels of the entire pathway 
members, which can be either up- or downregulated, and the clustergram highlights genes 
that were upregulated after NDV infection. All expression data can be found in 
Supplementary Materials. 
 
CRISPR-Cas9 engineering and screening of mutated murine cancer cell lines 
Rig-I (Ddx58) and Ifnar1 genes were disrupted with double-guided wild-type Cas9. Guide 
RNAs were designed against critical exons within each gene with proprietary software 
(AstraZeneca). Both guides were synthesised and cloned into DNA 2.0 vectors, one 
containing wild-type Cas9-2A-GFP (Rig-I) and the other wild-type Cas9-2A-RFP (Ifnar1). 
The two plasmids were transfected as single complexes into CT26 cells (American Type 
Culture Collection) with Lipofectamine LTX (LifeTechnologies), and after 3 days single cells 
were sorted on a FACSAria sorter (Becton Dickinson) for GFP-RFP double-positive cells 
into 96-well plates. Colonies were imaged by whole-well imaging on an IncuCyte Zoom 
(Essen BioScience), and colonies with average growth rates were selected for target 
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disruption screening. Gene disruption was assessed by either western blotting or FACS 
expression, and respective target loss of function was confirmed by DNA sequencing. 
 
Flow cytometry on in vitro and ex vivo samples 
Animals were euthanized and spleens were removed and dissociated to a single-cell 
suspension through a 70-µm nylon mesh. Tumors were dissociated with a commercial kit 
(Miletenyi Biotech). Cells were stained with a fixable live/dead dye (Life Technologies), 
followed by blocking with anti-CD16/32 antibody (eBiosciences) and staining with cocktails 
of fluorescence-conjugated antibodies before fixation in 1% formaldehyde–phosphate-
buffered saline (PBS). Intracellular nuclear staining was carried out on fixed and 
permeabilised cells (FoxP3/Transcription Factor Staining Buffer Set; eBioscience). Stained 
cells were analysed by flow cytometry (LSR Fortessa; BD Biosciences) and data analysis was 
performed in FlowJo software (Tree Star). Positive-staining gates were identified by 
comparison with cells stained with the full antibody panel minus the antibody of interest (FL-
1 control). In vitro cells were washed once in PBS and then incubated in nonenzymatic cell 
dissociation solution for 10 min before being neutralised in relevant media, washed, and 
resuspended in PBS before staining was performed as described above. A representative 
gating strategy is shown in Supplemental Fig. S6. 
 
Live imaging of NDV-GFP–infected cells 
After infection with NDV-GFP at MOIs described above, cells were imaged with one field 
per well every 3 h on an IncuCyte Zoom (Essen BioScience), and viral GFP expression was 
quantified in each cell line in real time and at various times over a period of 96 h. 
 
Statistical calculation 
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All in vivo data were collated in Excel (Microsoft) and transferred to Prism (GraphPad 
Software) for graphical representation. Tumor volumes were log transformed before 
statistical analysis. For comparison of tumor growth inhibition between groups, significant P 
values, if any, were obtained from two-way analysis of variance corrected with the Tukey test 
for multiple comparisons. Results from survival studies were analysed with a log rank 
(Mantel-Cox) test, comparing only two survival curves at a time. P values were not adjusted 
for multiple testing. Where means of two groups were compared then statistical analysis was 




NDV drives a potent tumor intrinsic inflammatory phenotype 
To test the oncolytic potency of MEDI5395, virus replication and oncolysis was measured 
across 176 human tumor cell lines, of which 82 (46%) showed >40% cytotoxicity/cell death 
72 h after infection (Fig. 1a). Using GM-CSF levels as a surrogate of virus replication (>10 
ng/mL), we found that MEDI5395 infected 146 of 176 (83%) cell lines (Fig. 1a). To 
investigate the contribution of the GM-CSF transgene to oncolysis we compared the 
oncolytic activity of MEDI5395 with a murine surrogate (NDVmuGM-CSF), since human 
GM-CSF is not bioactive in mice
14
. NDVmuGM-CSF exhibited equivalent oncolytic potency 
across all cell lines tested, indicating that GM-CSF did not contribute to oncolytic activity 
(Supplemental Fig S2c-d). To further demonstrate the oncolytic potency of MEDI5395, 
repeat local intratumoral (IT) and systemic administration regimens of MEDI5395 were 
tested in vivo in a patient derived triple negative breast cancer (TNBC) xenograft model 
(Supplemental Fig S1). Irrespective of the route of administration, both MEDI5395 and 
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NDVmuGM-CSF demonstrated potent oncolytic activity that was dependent on the ability of 
the virus to replicate. 
 
Five of the most sensitive cell lines (HT1080, DU145, CAL27, NCI-H358, and OVCAR4) 
were selected to further understand pathways that are altered after NDV infection (Fig 1b).  
These cells were infected with an NDV that can express green fluorescent protein (GFP)– 
(NDV-GFP) at multiplicities of infection (MOIs) resulting in 100% infection, then assessed 
24 h post infection for alterations in gene expression by transcriptomic microarray analysis 
(Affymetrix). More than 50% (11/20) of the most significantly altered pathways were 
involved in immune regulation. Hierarchical clustering of the 90 genes involved in these 
immune regulatory pathways segregated the cell lines into uninfected and infected groups 
(Fig. 1c). Gene expression changes in infected cells were confirmed by reverse transcriptase–
polymerase chain reaction. As expected, genes involved in RNA virus–sensing, (RIG-I and 
IRF7) were upregulated alongside genes known to be downstream of a type I IFN (IFN-I) 
response ISG15, CCL5 and CXCL11, which have previously been demonstrated to drive a 
proinflammatory response in vivo
15,16
 (Fig. 1d). Further analysis of cell surface and secreted 
proteins by flow cytometry and protein arrays, respectively, demonstrated that alterations in 
gene expression were matched by changes in protein levels. NDV-GFP–infected cells 
upregulated HLA-A, HLA-E, PD-L1, ICAM, and NKG2D ligands, all of which have been 
implicated in modulating the immune system
17,18
 (Fig. 1e). Upregulation of the chemokines 
CCL5 (P<0.0001 in all 5 cell lines), CXCL10 (P<0.0001 in all 5 cell lines), and CXCL11 
(P<0.0001 in HT1080 and OVCAR4 cell lines) was also confirmed following analysis of cell 
supernatants collected from NDV-GFP–infected tumor cells (Fig. 1f). These data suggest 
that, in addition to a direct cytolytic effect, infection of tumor cells by MEDI5395 may lead 
to immune-modulation through multiple pathways. 
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To further investigate the hypothesis that MEDI5395 exerts a proinflammatory effect in 
tumors, sensitivity to MEDI5395 infection was profiled in 11 syngeneic mouse cell lines. 
Sensitivity to MEDI5395 was greatly reduced in murine tumor cell lines compared with 
human cell lines; in line with data reported for other OV’s including Maraba and Vesicular 
Stomatitis Viruses
19
. Nonetheless, transgene expression could be detected in most murine 
tumor cell lines 72 h after infection at MOI 0.1 (Supplemental Fig. S2a). Infection of these 
syngeneic mouse cell lines with MEDI5395 at MOI of 10 conferred broadly equivalent levels 
of oncolytic activity to that detected following infection of the human HT1080 cell line 
(Supplemental Fig. S2b). No difference in sensitivity to MEDI5395 or NDVmuGM-CSF, was 
observed in murine tumor cell lines (Supplemental Fig. S2e). 
 
Despite reduced susceptibility, 100% infectivity of syngeneic murine cells could be achieved 
with NDV-GFP 24 h post infection by using higher MOIs than in the human tumor cell 
studies. Gene expression analysis of infected and uninfected tumor cells revealed that of the 
15 differentially regulated pathways identified in syngeneic cell lines, 12 matched those 
identified in human tumor cell lines, and all were immune modulatory pathways 
(Supplemental Fig. S4). Expression levels of these immune pathway genes were again 
segregated into uninfected and infected cells after cluster analysis (Supplemental Fig. S3a). 
Immune cell surface markers PD-L1 and MHC-I were also upregulated after infection of 
these murine cell lines (Supplemental Fig. 2b). Although the pattern of altered gene 
expression associated with the anti-viral response was similar between human and murine 
tumor cell lines, the absolute levels of changes in gene and protein expression between 
uninfected and infected murine tumor cells were several orders of magnitude larger than 
those observed in human cell lines. Potentially this may be one mechanism by which murine 
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tumor cell lines suppress replication and virus spread to neighbouring cells (Supplemental 
Fig. S3d). Therefore, although sensitivity to MEDI5395 differed between mouse and human 
tumor cell lines, activation of similar pathways and cellular responses resulted at matched 
effective MOIs. 
 
NDVmuGM-CSF modulates the TME resulting in antitumor activity in vivo 
Three murine syngeneic tumor models, that differed in both their in vitro response to 
MEDI5395 and their in vivo immune TME profiles, were chosen to evaluate the antitumor 
efficacy of NDV. (i) CT26 model, characterised as immune responsive (inflamed TME, but 
low sensitivity to NDV); (ii) the B16F10 model (cold TME, most sensitive mouse cell line to 
NDV); and (iii) the 4T1 model (“immunosuppressed” TME, insensitive to NDV)
20
 
(Supplemental Fig. S2a). To reproduce the high MOIs required to observe any lytic activity 
in the mouse tumor cell lines in vitro, direct delivery of NDVmuGM-CSF into sub-
cutaneously implanted tumors via IT route was utilised. 
 
In the CT26 model, despite limited replication, NDVmuGM-CSF treatment resulted in 
significant antitumor activity and an increase in median survival times (P=0.006), from 22 
days in untreated controls to 30.5 days in NDVmuGM-CSF–treated animals; 2/12 animals 
had complete tumor regression, compared with no animals in the untreated control group 
(Fig. 2a). In the B16F10 model, tumor growth inhibition was observed in all treated animals 
during treatment, but the benefit was rapidly lost after treatment cessation. Anti-tumor 
activity resulted in a significant increase in median survival times (P=0.0002), from 18 days 
in untreated controls to 23 days in NDVmuGM-CSF treated animals, but no complete 
responses were observed (Fig. 2b). Finally, in the 4T1 model, the least sensitive cell line, a 
modest but reproducible anti-tumor effect (25% reduction, P=0.0071) was achieved (Fig. 2c). 
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Similar antitumor activity in these models was observed following treatment with MEDI5395 
(Supplemental Fig S3d-e). 
 
Flow cytometric immune-phenotyping of resected tumors, 24 h after the third IT 
administration of NDVmuGM-CSF revealed that several immune-cell populations present in 
the TME were differentially modulated; in a model-dependent manner (i.e., significantly 
altered in only one or two of the three models) following NDVmuGM-CSF treatment. 











) within the TME were significantly reduced by 1.8- to 3-fold 
and 2.2- to 2.5-fold, respectively, compared with untreated controls (Fig. 2d and e) across all 
three models after NDVmuGM-CSF treatment.  
NDV also modulated the tumor resident/infiltrating T cell compartment. NDVmuGM-CSF 
treatment in CT26 and B16F10 tumor bearing mice conferred a significant increase in the 













(1.4- and 2.8-fold, respectively) observed in the TME compared to untreated controls (P= 
0.0359 and 0.0192 respectively; Fig. 2h). Notably, rechallenge of NDVmuGM-CSF treated 
CT26 tumor bearing mice with a second inoculation of CT26 cells on the opposite flank, 
failed to induce tumor development (Fig. 2i); reflective of protective immunological memory. 
In addition animals who were rechallenged with CT26 had higher number of T cells that 
reacted to the dominant CT26 peptide AH1 (REF) as judged by increased number of IFN-γ 
positive “spots” (Fig. 2j),  indicating that a proportion of T cells now recognise tumor 
antigens. 
Virally infected cells were identified by FACS using an anti-NDV hemagglutinin-
neuraminidase (vHN) antibody. FACS analysis identified not only vHN-positive tumor cells 
but also vHN-positive myeloid populations (macrophages, DCs, and neutrophils) in all three 
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models (Fig. 2e and f). Virus infection was associated with a significant upregulation of PD-
L1 on the surface of vHN
+
 myeloid populations within the TME compared with untreated 
animals (Fig. 2g). 
To better understand the adaptive immune response observed in CT26 tumors, we explored 
the T cell receptor (TCR) repertoire following viral infection in tumor-bearing mice. Mice 
were received 3 IT administrations of 5× 10
8
pfu of NDVmuGM-CSF, and the TCR repertoire 
from tumors and spleens were analysed 7 days after the final injection. Enhanced TCR 
clonality was only observed in spleens of CT26 tumor bearing mice treated with 
NDVmuGM-CSF; indicating a systemic effect to local administration of NDVmuGM-CSF 
(P=0.011; Fig. 2k). Using the number of TCR copies as a surrogate for number of 
resident/infiltrating T cells revealed a significant increase in T cell number within 
NDVmuGM-CSF infected tumors compared with controls (P=0.02; Fig. 2l), This correlates 
with a significantly reduced clonal TCR repertoire within NDVmuGM-CSF treated tumors 
(P=0.007; Fig. 2m), suggesting that the T cell response may be focussed against specific 
antigens (virus or tumor derived) present within the TME. There was a significant overlap in 
TCR sequences isolated from tumor and spleens indicating that T cell clones from the 
periphery are infiltrating infected tumors (P=0.0081; Fig. 2n). Comparison of shared 
sequences between NDVmuGM-CSF treated individuals was indicative of an adaptive 
immune response that was conserved between individual animals (Fig. 2p). 
 
NDV sensitises tumors to immune checkpoint blockade and T cell agonist agents 
Given the immune-modulatory effects observed with NDVmuGM-CSF we next explored 
whether the antitumor response could be augmented by combination with either anti-PDx 
(PD-L1 or PD-1) antibodies or T cell agonists. To test this hypothesis, NDVmuGM-CSF was 
combined with either an anti–PD-1 or an anti–PD-L1 antibody (Fig. 3a). NDVmuGM-CSF 
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monotherapy significantly increased median survival time to 38 days compared to 29 days in 
vehicle control group (P=0.277) whilst anti-PD-1 and PD-L1 treatment alone increased 
median survival time to 44 days and 36 days respectively (P=0.005 & P=0.077). The 
combination of NDVmuGM-CSF with anti-PD-1 resulted in a significant increase in median 
survival time compared to either PD-1 (P=0.0499) or NDVmuGM-CSF (P=0.007) 
monotherapy. The combination of NDVmuGM-CSF with anti-PD-L1 resulted in a significant 
increase in median survival time compared to either PD-L1 (P=0.025) or NDVmuGM-CSF 
(P=0.041) monotherapy. No significant difference in efficacy was observed between the 
NDVmuGM-CSF and PD-L1 or NDVmuGM-CSF and PD-1 combination groups (Fig. 3b, c, 
and d).  
To examine the combination potential of NDV with T cell agonists; NDVmuGM-CSF was 
combined with a murine GITR ligand fusion protein (mGITRL-FP) or a murine OX40 ligand 
fusion protein (mOX40L-FP)
22,23
. Combining NDVmuGM-CSF with mGITRL-FP, which 
had no antitumor activity as a monotherapy (Fig. 3e, f) resulted in a significant increase in 
median survival times compared to vehicle (22 days, P<0.001) and either mGITRL-FP (21 
days, P=0.0018) or NDVmuGM-CSF (32.5 days, P=0.0300) monotherapy. Notably, 
treatment with the combination of NDVmuGM-CSF and mGITRL-FP resulted in complete 
regression of tumors as large as ~700 mm
3
 (Fig. 3g).  NDVmuGM-CSF combined with 
mOX40L-FP resulted in a significant increase in median survival times compared to vehicle 
(17 days, P<0.0001) or either mOX40L-FP (19 days, P<0.0001) or NDVmuGM-CSF (36 
days, P=0.0075) monotherapy (Fig. 3h-j). These data indicate that NDVmuGM-CSF can 
enhance the activity of multiple immunotherapeutic agents and support the clinical evaluation 
of several IO combination strategies with MEDI5395.  
 
Enhanced viral replication delivers enhanced antitumor activity in vivo 
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Due to the intrinsic differences between murine and human tumor cells to support NDV 
replication and oncolysis, currently there is no suitable preclinical model that can be used to 
explore oncolytic activity or sustained expression of the therapeutic GM-CSF transgene 
(which is driven by virus replication) in the presence of a fully intact immune system. In an 
effort to enhance virus susceptibility in murine cell lines, the retinoic acid–inducible gene I 
(Rig-I) and IFN-α/β receptor subunit 1 (Ifnar1) genes were deleted in a CT26 syngeneic 
tumor line using CRISPR gene editing. Successful targeting of both loci and complete loss of 
protein expression were determined by western blot and flow cytometry, respectively 




 clones were functionally screened 





 cells were able to support greater levels of virus replication compared 
to the parental cell line for at least 96 h, as measured by GFP intensity on a per-cell basis 





at 72 h (Fig. 4b). At 72 h after infection with MEDI5395, there were significantly higher 
levels of infectious virus particles (>2 log) and GM-CSF (GM-CSF) transgene protein (>2-




 supernatants than in the parental cell line (Fig. 4c). This 
enhanced virus replication did not result in significantly increased oncolytic activity at 72 h 
(Fig. 4d). However, a decrease in cell survival was observed at 96 h after infection, 
demonstrating that the engineered cell lines remained less sensitive than the control human 





cells with an NDV-luciferase virus revealed that enhanced susceptibility to NDV infection 
was retained in vivo after a single IT administration (Supplementary Fig. S5f and g). An 
enhancement in levels of viral replication combined with a limited impact on sensitivity to 
oncolysis were observed when these two deletions were introduced into the B16F10 
syngeneic cell lines (Supplemental Figure S5c-e).  
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 modified model had similar tumor growth kinetics and 
survival times to those of the CT26 parental tumors (Fig. 4f and g). NDVmuGM-CSF IT 





tumors compared to CT26 parental tumors (P<0.0001). Complete responses were observed in 




 tumor-bearing animals compared with 22% (4/18) in 
CT26 parental tumors (Fig. 4f and g). Enhanced viral replication within these cells did not 
negatively impact the host’s ability to mount an effective antitumor immune response against 
rechallenge (Fig. 4h). These data indicate that increased virus replication is associated with 
significant improvement in antitumor activity in the immunocompetent setting. 
 
 
Potentiation of systemic antitumor effects by increased susceptibility to NDVmuGM-
CSF 
To assess the ability of local NDVmuGM-CSF treatment to generate an immune response 
capable of leading to systemic therapeutic responses including in non-injected “anenestic” 
tumors and understand whether this was affected by the level of virus replication, CT26 




 cells were implanted and tumors established on both 
flanks of BALB/c mice. NDVmuGM-CSF was then administered IT only in the right-flank 
tumor (Fig. 5a). In the parental CT26 model, a small proportion of treated right-flank tumors 
responded to treatment, but untreated left-flank tumors grew unimpeded and no survival 




 treated tumors 
responded to local administration of NDVmuGM-CSF, and complete regression of untreated 
left-flank tumors in 20% (2/10) of animals was also observed (Fig. 5b). Median survival in 
the NDVmuGM-CSF–treated tumors were also significantly increased, compared to the 
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vehicle control group (P =0.0031; Fig. 5c). Similar response rates and activity was observed 
with MEDI5395 (Supplemental Figure S5k). 
 




 model no evidence of virus replication was found at 
any time point in the left flank (untreated, anenestic) tumor by bioluminescence imaging 
following IT injection of the contra-lateral tumor with NDV-luciferase (Fig. 5d). The absence 
of viral infection in untreated/uninjected tumors was further confirmed with flow cytometry 
24 h after the third dose. NDV vHN protein was detected only on the surface of treated (right-
flank enestic) tumors and was associated with a significant upregulation of PD-L1 on the 
surface of infected cells (P=0.001), whereas no alterations in PD-L1 levels was observed in 
vHN-negative, untreated left-flank tumors (Fig. 5e and f). Increased numbers of infiltrating 
neutrophils were detected in the treated right-flank tumors (P=0.0005) and these 
polymorphonuclear cells tended to be positive for vHN protein on their cell surface (Fig. 5g 
and h). CD8
+
 T cells with a “reinvigorated” phenotype were also significantly upregulated, 
but only in the treated right-flank tumors (P<0.0001; Fig. 5i). However, Treg proportions were 
significantly reduced in both treated right-flank (P=0.001) and untreated left-flank tumors 
(P=0.013; Fig. 5j). This reduction in immune suppressive potential within the TMEs of both 





 T cells observed both in treated (P<0.0001 & 0.0017 respectively) and 
untreated (P=0.0015 & 0.0016 respectively) tumors (Fig. 5k). The data suggests that the 
anenestic effect is not due to the ability of virus to replicate at distal un-injected sites after 
local administration, but the ability of NDV to prime and activate a systemic antitumor 
immune response at the site of the injected tumor. 
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The paradigm underlying the mechanism of OVs in the clinical setting has undergone a 
radical transformation over the last decade. Historically, interactions between OV vectors and 
host immunity were thought to be antithetical to the antitumor activity of OVs. This opinion 
has altered, with the advent of ICB therapy demonstrating that modulation of the host 
immune system results in durable antitumor responses in some patients. Indeed, it is now 
understood that the ability of OVs to combine potent immune activation and modulation with 
direct tumoricidal activity is one of the key properties of this class of  immunotherapy agents. 
Therefore achieving the optimal balance between these two distinct mechanism of actions is 
the greatest challenge for successful clinical development
9
.  
We show that MEDI5395 has potent and broad oncolytic activity across a range of solid 
human tumor types in vitro. Cell lines from haematological malignancies appear comparably 
in-sensitive to the oncolytic action of MEDI5395, recapitulating findings made with other 
OVs including pexastimogene-devacirpvec
24
. Further stratification of the haematological cell 
lines used in the screen revealed that sensitivity to MEDI5395 appears restricted to myeloid 
lineage malignancies, a phenomenon previously reported for other viruses 
25
.  
Despite the limitations of in vitro screening for estimating efficacy with an OV, this can be 
used to identify potential mechanisms of insensitivity/sensitivity to OV replication and 
oncolysis. Interestingly, we found that several colorectal cancer cell lines were resistant to 
MEDI5395-induced cell lysis, but still able to support high levels of viral replication. 
Extending the assay beyond 72 hrs led to increased cell death (Supplemental Figure S2F), 
suggesting that these cells may have delayed cell death kinetics rather than intrinsic 
resistance to MEDI5395-mediated oncolysis, perhaps as a consequence of defects in 
apoptosis/necroptosis pathways that are required for efficient NDV-induced death
26
. 
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Furthermore, infected tumor cells are likely to be immunologically “visible” and susceptible 
to immune-mediated clearance. Therefore, a simplified cell screen, that measures only tumor 
cell death and only over a short time period in vitro, may substantially underestimate actual 
antitumor activity in the clinical setting.  
RNA viruses, such as NDV, are potent inducers of type I IFNs 
11
. Accordingly, we show that 
MEDI5395 infection led to increased expression of gene signatures associated with type I 
IFN pathway activation and release of additional proinflammatory cytokines and chemokines. 
Transcriptomic data indicated that the inflammatory phenotype induced in tumor cells after 
MEDI5395 infection is similar to that engendered by viral pathway mimetics or agonists of 
RIG-I and STING
27,28
. These mimetic strategies can produce potent antitumor responses in 
pre-clinical models through DC activation and enhanced tumor-specific CD8
+
 T cell 
responses
29
. Consistent with this, an attenuated NDV has previously demonstrated strong 
antitumor efficacy in preclinical models, driven by its ability to modulate the TME and 
synergise with ICB to drive potent anenestic responses
30,31
. MEDI5395 also induced 
significant antitumor activity in vivo; even in murine tumor models, where virus replication is 
relatively restricted (Fig. 2a–c). Importantly, we clearly demonstrated that MEDI5395 
generated potent adaptive immune responses, as indicated by the following: (i) protective 
effect against re-challenge; (ii) increased TCR diversity in the tumor; (iii) re-invigoration of 
tumor infiltrating CD8
+
 T cells; (iv) systemic anenestic effect in the dual-flank model. 
We also demonstrated that NDVmuGM-CSF infection modulated the immune contexture of 
the TME in vivo, as evidenced by the pronounced effect on Treg and DC infiltrate densities 
relative to tumors derived from vehicle treated animals (Fig. 2d). This does not appear to be a 
direct effect of Treg infection and lysis by NDV 
13
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ICB therapy with PDx has transformed the standard of care across a range of cancers. 
However, whilst effective for some patients, many patients either fail to respond to PDx 
therapy or suffer from disease relapse. In preclinical models we show that NDVmuGM-CSF 
infection leads to systemic T cell priming, as measured by an increased TCR clonality in the 
spleen, expansion of tumor-infiltrating T cells commensurate with increased type I and II IFN 
production, and increased PD-L1 expression on tumor and myeloid cells within the TME. 
Moreover, our data demonstrate that the capacity of NDVmuGM-CSF infection to alter the 
TME through conversion of an immunologically cold to an inflamed tumor may be used to 
increase both the frequency of patients responding to PDx blockade and depth of response. 
Alongside ICB agents, T cell agonists also continue to be investigated in the clinic, though 
initial clinical response has been disappointing
33
. Combining T cell agonists with OVs could 
simultaneously reduce immune-suppressive mechanisms within the TME and prime T cells to 
new tumor-associated antigens, which may result in improved clinical benefit. Not all OVs 
appear to synergise with T cell agonists; VSV-IFNβ has been shown to have no activity when 
combined with an OX40L agonist in preclinical models, because OX40L primes an antiviral 
rather than an antitumor response
34
. This is in contrast to our findings with MEDI5395 where 
combinations of NDVmuGM-CSF and GITRL or OX40L agonists were significantly more 
effective than monotherapies in syngeneic tumor models. 
Modelling the therapeutic activities of these OVs in preclinical tumor models remains a key 
challenge in the field, owing to the naturally variable tropism across virus species and the 
lack of relevant preclinical pharmacology animal models for OV investigations. Enhanced 
susceptibility to MEDI5395 (driven by loss of Rig-I and Ifnar1 genes involved in antiviral 




 cells that were 
able to support significantly greater levels of virus replication than the parental cell line in 
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vitro and in vivo resulted in significantly improved antitumor efficacy. This enhanced activity 
of NDVmuGM-CSF in engineered cell lines was not entirely dependent on oncolysis.  
In the dual flank tumor setting, antitumor activity in untreated (anenestic) lesions was 
observed only when tumor cells had a higher capacity to support virus replication. This 
activity was accompanied by an apparent enhanced antitumor immune response that resulted 
in changes within the immune contexture of the untreated lesion in the absence of any 
evidence of virus replication. 
In summary, MEDI5395 demonstrated potent oncolytic properties across a broad spectrum of 
human and murine cancer cell lines and patient derived xenograft models. The ability of 
MEDI5395 to lyse cancer cells and simultaneously modulate the immune system results in 
significant antitumor activity in vivo, which can be further augmented when the virus is 
administered in combination with immune-modulating antibodies. These preclinical data 
support clinical development of MEDI5395; both as a monotherapy and in combination with 
other immuno-oncology agents.   
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Fig. 1. MEDI5395 combines broad oncolytic activity with induction of immunological changes 
within tumor cells in vitro. a Output from >100 human cell lines infected with MEDI5395 at MOI 
0.1. Shown is potency of virus classified as percent kill (symbol colour) at 72 h after infection and 
GM-CSF levels in supernatant (symbol size), which was used as a surrogate of susceptibility to virus. 
1 = CAL27, 2 = NCI-H358, 3 = OVCAR4, 4 = DU145, and 5 = HT0180 cell lines. Each data point is 
an average of three individual replicates. b Fifty percent inhibitory concentration (IC50) curves from 
the five sensitive cell lines identified in a at 72 h after infection with MEDI5395. Data represent the 
mean of four biological replicates for each cell line. c Clustergram analysis of RNA expression of 96 
genes involved in immune-cell interactions at 24 h after infection at MOIs that resulted in 100% 
infection. d Reverse transcriptase–polymerase chain reaction analysis of gene expression expressed as 
fold change relative to untreated levels at 24 h after NDV-GFP infection at MOIs that resulted in 
100% infection; n = 6 per group. Data are mean ± standard error of the mean (SEM). e Representative 
FACS analysis histogram plots of cell surface marker expression at 24 h after NDV-GFP infection 
from one of the five sensitive cell lines (CAL27). f Levels of CCL5, CXCL10, and CXCL11 protein 
in supernatants from the same NDV-GFP–infected cells shown in d at 24 h after infection. Statistical 
analysis was performed with an unpaired t test with Welch correction; data are mean ± SEM. *, P < 




Fig 2 NDV infection remodelling of TME leading to immune-mediated antitumor activity. a 
Tumor volumes after IT dosing with NDVmuGM-CSF in CT26 (n = 12), b B16F10 (n = 10), and c 
4T1 (n = 10) syngeneic tumor models. Dashed vertical lines represent days of NDVmuGM-CSF 
injections (5 × 108 pfu). CT26 tumor growth data (mean ± SEM) shown as spider plots demonstrating 
heterogeneous antitumor response. d Representative immunophenotyping of tumor immune infiltrate 
from three syngeneic models at 24 h after third IT dose of 5 × 108 pfu at 8, 11, and 14 days post 
implantation; n = 6 vehicle and 6 treated animals for each model. Data are mean ± SEM log2 values 
relative to untreated cell counts. NK = natural killer cells; CD19 = B cells; Mθ = macrophage. e 
Representative pseudocolour dot plots showing Treg proportions in treated tumors and presence of 
NDV vHN protein on infected tumor cell surfaces. f vHN protein expression (MFI) on cell surface of 
myeloid cell subsets in TME. Data are mean ± SEM. g PD-L1 expression (MFI) on the surface of 
myeloid cell subsets in TME. Data are mean ± SEM. h Detection of “re-invigorated” (PD-1+, Eomes+, 
Ki67+, Gzmb+) CD8+ T cells in TME. Data are mean ± SEM; *, P < 0.05. i Tumor growth plots from 
control CT26 tumor-bearing animals or rechallenged CT26 “cured” animals after NDVmuGM-CSF 
treatment with CT26 cells on opposite flank. Data represent two separate experiments (controls, n = 3; 
rechallenged, n = 6). j Detection of AH1 reactive T cells from splenocytes isolated from control or 
previously “cured” NDVmuGM-CSF treated animals following CT26 tumor rechallenge as judged by 
increased number of IFN-γ positive “spots” following stimulation with (red) or without (blue) AH1 
peptide ex vivo. Data are mean ± SEM (n=2 per group). k and l Clonality of TCR sequencing isolated 
from k spleen and l tumor. Values approaching 1 indicate a nearly monoclonal population of TCRs 
(controls, n = 8; virus treated, n = 7). m Comparison of T cell clonality from vehicle- and 
NDVmuGM-CSF–treated tumors. n Morisita index quantitates the similarity between TCR repertoires 
in spleen and tumors of vehicle- and NDVmuGM-CSF–treated mice. p Comparison of shared TCR 
sequences between individual animals in untreated and treated groups. For all comparisons between 
two data sets, statistical analysis was performed with unpaired t test with Welch correction. *, P < 
0.05; **, P < 0.01; ***, P < 0.001. 
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Fig 3 Combination of NDV with immune checkpoint blockade or T cell agonists in pre-clinical 
models. a Schematic representation of study design combining local NDVmuGM-CSF administration 
with antibodies to PD-1 or PD-L1 in the CT26 model. IT. = intratumoral; IP. = intraperitoneal. b 
Spider plots showing tumor growth kinetics in individual animals in each group (n = 10 per group), 
data is representative of 3 separate experiments. c, d Kaplan-Meier survival analyses of NDVmuGM-
CSF plus c anti–PD-1 or d PD-L1 antibody combination therapy compared with monotherapies. e 
Schematic representation of study design combining NDVmuGM-CSF administration with mGITRL-
FP agonist in the CT26 model. f Spider plots showing tumor growth kinetics of the individual animals 
in each group (n = 10 per group except NDVmuGM-CSF, n = 18). g Kaplan-Meier survival analysis 
of NDVmuGM-CSF plus mGITRL-FP agonist combination therapy compared with vehicle control 
and NDVmuGM-CSF and mGITRL-FP monotherapies. h Schematic representation of study design 
combining local administration of NDVmuGM-CSF with mOX40L-FP agonist in CT26 model. i 
Spider plots showing tumor growth kinetics of the individual animals in each group (n = 10 per group 
except NDVmuGM-CSF and NDVmuGM-CSF + OX40L-FP, n = 18). j Kaplan-Meier survival 
analysis of NDVmuGM-CSF plus mOX40L-FP agonist combination therapy compared with 
monotherapy. CR = complete response; PD = progressive disease; PR = partial response. Significance 
in survival was assessed by log rank (Mantel-Cox) test. *, P < 0.05; **, P < 0.01; ****, P < 0.0001. 
 
Fig 4 Genetic modifications of syngeneic tumor cells modulates susceptibility to NDV infection 
in vitro and in vivo. a Quantitative measurement of GFP intensity per individual cell over time after 
infection of CT26 Rig-I–/–, Ifnar1–/– cells with NDV-GFP. b Representative Incucyte images of CT26 
parental and Rig-I–/–, Ifnar1–/– (clone 2) cells at 72 h after infection with NDV-GFP at MOI 0.1. c 
hGM-CSF transgene expression levels (top) and virus titres (bottom) at 72 h after infection at MOI 
0.1 from parental CT26 cell line and a CT26 Rig-I–/–, Ifnar1–/– clones. Data represents four separate 
experiments. *, P = 0.05; ****, P < 0.0001; NS, not significant. d Oncolytic potency of MEDI5395 
(percent cell survival) in CT26 parental and CT26 Rig-I–/–, Ifnar1–/– clones. Data represents four 
separate experiments. e Comparison of percent cell death observed over 96 h after MEDI5395 
infection at MOI 0.1 in CT26 and CT26 Rig-I–/–, Ifnar1–/– clone 2 versus HT1080 human xenograft 
cell line. Data represents two separate experiments. f Representative spider plots showing tumor 
growth kinetics of individual animals implanted with CT26 parental cells (blue lines) or CT26 Rig-I–/–
, Ifnar1–/– cells (green lines), alongside growth kinetics from CT26 parental tumors (red lines) and 
CT26 Rig-I–/–, Ifnar1–/– tumors (purple lines) treated with IT NDVmuGM-CSF at 5 × 108 pfu. Vertical 
dashed lines represent days of dosing. CR = complete response; PD = progressive disease; PR = 
partial response. g Kaplan-Meier survival analysis of untreated and NDVmuGM-CSF–treated animals 
implanted with the indicated tumor. h Tumor growth kinetics after rechallenge of “cured” CT26 Rig-
I–/–, Ifnar1–/– tumor-bearing animals with new CT26 Rig-I–/–, Ifnar1–/– cells on the opposite flank (red 
lines; n = 6), compared with tumors grown n naïve animals (blue lines; (n = 3). Significance in 
survival was assessed by log rank (Mantel-Cox) test. 
 
Fig 5 Increased susceptibility to NDV was required to generate potent anenestic antitumor 
responses, which were entirely dependent on modulation of the host immune system. a 
Schematic representation of study design with NDVmuGM-CSF administered in a dual-flank CT26 
Rig-I–/–, Ifnar1–/– tumor model. b Mean tumor growth in untreated animals (blue lines) and spider 
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32 
plots from individual NDVmuGM-CSF–treated animals (red lines) in both treated tumors (solid lines) 
and untreated tumors (dashed lines) (n = 10 animals per group). CR = complete response; PD = 
progressive disease; PR = partial response. c Kaplan-Meier plot of survival proportions in dual flank 
model. d Representative image of bioluminescent signal detected in NDV-luciferase–treated animals 
at 48 h after a single IT administration of virus at 5 × 108 pfu (n = 10). Immunophenotyping of treated 
and untreated tumors with three IT doses of NDVmuGM-CSF was performed on days 8, 11, and 14 
after implantation and then analysed 24 h later on day 15. e–j Detection of e vHN protein and f PD-L1 
from NDVmuGM-CSF on surface of CD45– tumor cells. f Detection of PD-L1 on surface of tumor 
cells. g Detection of neutrophils (CD11b+, Ly6Ghi) within tumors and h analysis of vHN levels on the 
surface of tumor-infiltrating neutrophils. i Detection of “reinvigorated” T cells and j Tregs within 
tumors. Blue solid squares, vehicle-treated tumors; blue open squares, untreated tumors; red solid 
circles, NDVmuGM-CSF–treated tumors; red open circles, untreated tumors. MFI = mean 
fluorescence intensity. k Quantification of Ki67+, CD4+, and CD8+ T cell populations in vehicle-
treated (solid blue bars) and untreated (shaded blue bars) tumors and in NDVmuGM-CSF–treated 
(solid red bars) and untreated (shaded red bars) tumors (n = 8 animals per group). Statistical analyses 
were performed with an unpaired t test with Welch correction; data are mean ± SEM. **, P < 0.01; 
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